Free Trial
→ Musk's shopping list: batteries ✓ solar ✓ data ✓ power ___ (From Behind the Markets) (Ad)tc pixel Free BACK Stock Alerts

IMAC (BACK) Competitors

IMAC logo
$0.05 0.00 (0.00%)
As of 05/22/2026
Compare

BACK vs. DHAC, NIVF, BTTX, UPHL, and ACONW

Should you buy IMAC stock or one of its competitors? MarketBeat compares IMAC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IMAC include Digital Health Acquisition (DHAC), NewGenIvf Group (NIVF), Better Therapeutics (BTTX), UpHealth (UPHL), and Aclarion (ACONW). These companies are all part of the "healthcare" industry.

How does IMAC compare to Digital Health Acquisition?

IMAC (NASDAQ:BACK) and Digital Health Acquisition (NASDAQ:DHAC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

IMAC has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, Digital Health Acquisition has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
Digital Health Acquisition N/A N/A N/A

5.8% of IMAC shares are owned by institutional investors. Comparatively, 1.0% of Digital Health Acquisition shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Comparatively, 6.6% of Digital Health Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, IMAC's average media sentiment score of 0.00 equaled Digital Health Acquisition'saverage media sentiment score.

Company Overall Sentiment
IMAC Neutral
Digital Health Acquisition Neutral

Digital Health Acquisition has lower revenue, but higher earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K2.42-$9.42M-$3.12N/A
Digital Health AcquisitionN/AN/AN/AN/AN/A

Summary

IMAC beats Digital Health Acquisition on 4 of the 5 factors compared between the two stocks.

How does IMAC compare to NewGenIvf Group?

NewGenIvf Group (NASDAQ:NIVF) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

NewGenIvf Group has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewGenIvf Group$4.73M0.05$9.88MN/AN/A
IMAC$72.05K2.42-$9.42M-$3.12N/A

NewGenIvf Group has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, IMAC has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by insiders. Comparatively, 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
NewGenIvf GroupN/A N/A N/A
IMAC N/A N/A -325.44%

In the previous week, NewGenIvf Group had 9 more articles in the media than IMAC. MarketBeat recorded 9 mentions for NewGenIvf Group and 0 mentions for IMAC. IMAC's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.11 indicating that IMAC is being referred to more favorably in the news media.

Company Overall Sentiment
NewGenIvf Group Neutral
IMAC Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
IMAC
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

NewGenIvf Group beats IMAC on 7 of the 10 factors compared between the two stocks.

How does IMAC compare to Better Therapeutics?

Better Therapeutics (NASDAQ:BTTX) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
IMAC N/A N/A -325.44%

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
IMAC Neutral

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 12.3% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

IMAC has higher revenue and earnings than Better Therapeutics. IMAC is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.78N/A
IMAC$72.05K2.42-$9.42M-$3.12N/A

Better Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, IMAC has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market.

Summary

Better Therapeutics beats IMAC on 5 of the 8 factors compared between the two stocks.

How does IMAC compare to UpHealth?

UpHealth (NYSE:UPHL) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Company Net Margins Return on Equity Return on Assets
UpHealthN/A N/A N/A
IMAC N/A N/A -325.44%

In the previous week, UpHealth's average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.

Company Overall Sentiment
UpHealth Neutral
IMAC Neutral

UpHealth has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, IMAC has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market.

56.1% of UpHealth shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 34.2% of UpHealth shares are owned by company insiders. Comparatively, 12.3% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

IMAC has lower revenue, but higher earnings than UpHealth. IMAC is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UpHealth$130M0.00-$56.42M$1.470.00
IMAC$72.05K2.42-$9.42M-$3.12N/A

Summary

UpHealth beats IMAC on 6 of the 9 factors compared between the two stocks.

How does IMAC compare to Aclarion?

Aclarion (NASDAQ:ACONW) and IMAC (NASDAQ:BACK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

In the previous week, Aclarion's average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.

Company Overall Sentiment
Aclarion Neutral
IMAC Neutral

Company Net Margins Return on Equity Return on Assets
AclarionN/A N/A N/A
IMAC N/A N/A -325.44%

Aclarion has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclarion$77.88KN/AN/AN/AN/A
IMAC$72.05K2.42-$9.42M-$3.12N/A

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Aclarion and IMAC tied by winning 2 of the 4 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BACK vs. The Competition

Export
MetricIMACSpecialty outpatient clinics IndustryMedical SectorNASDAQ Exchange
Market Cap$174K$174K$6.46B$12.34B
Dividend YieldN/AN/A2.76%5.28%
P/E Ratio-0.01N/A21.2125.65
Price / Sales2.422.42554.3886.31
Price / CashN/AN/A43.4956.67
Price / Book-0.07N/A10.377.14
Net Income-$9.42M-$9.42M$3.57B$335.98M
7 Day PerformanceN/AN/A6.40%4.15%
1 Month PerformanceN/AN/A3.53%2.54%
1 Year PerformanceN/AN/A34.04%35.06%

IMAC Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BACK
IMAC
N/A$0.05
flat		N/A+39.4%$174K$72.05KN/A180
DHAC
Digital Health Acquisition
N/A$0.16
+6.9%		N/A-85.3%$575KN/AN/A2,021
NIVF
NewGenIvf Group
1.6844 of 5 stars		$1.02
-8.9%		N/A-99.9%$280K$4.73MN/AN/A
BTTX
Better Therapeutics
N/A$0.00
flat		N/AN/A$4KN/AN/A40
UPHL
UpHealth
N/A$0.00
-50.0%		N/A-66.7%$2K$130MN/A1,750

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BACK) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel